Phaseline

Targets › PAP

PAP (Poly(A) polymerase alpha): drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.

Polymerase that creates the 3'-poly(A) tail of mRNA's. Also required for the endoribonucleolytic cleavage reaction at some polyadenylation sites. (UniProt, P51003)

Open in Phaseline: the race on PAP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Wisconsin, MadisonpTVG-HP
Plasmid DNA vaccine encoding prostatic acid phosphatase (PAP)
PAPPhase 2Castration-resistant Prostate Cancer; Prostate Cancer; Prostate Cancer PatientsMar 2027

Conditions

Castration-resistant Prostate Cancer (1) Prostate Cancer (1) Prostate Cancer Patients (1)

Modalities

mixed (1)

Companies

University of Wisconsin, Madison (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.